Cal-D-or

Hauptinformation

  • Handelsname:
  • Cal-D-or 500 mg/400 I.E. - Kautabletten
  • Einheiten im Paket:
  • 20 Stück (HDPE-Behälter), Laufzeit: 36 Monate,60 Stück (HDPE-Behälter), Laufzeit: 36 Monate,120 Stück (HDPE-Behälter), Laufzeit:
  • Verschreibungstyp:
  • Arzneimittel zur wiederholten Abgabe gegen aerztliche Verschreibung
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Cal-D-or 500 mg/400 I.E. - Kautabletten
    Österreich
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiebereich:
  • Calcium, combinations wit
  • Produktbesonderheiten:
  • Abgabe durch eine (öffentliche) Apotheke

Weitere Informationen

Status

  • Quelle:
  • AGES
  • Zulassungsnummer:
  • 1-22817
  • Berechtigungsdatum:
  • 09-12-1998
  • Letzte Änderung:
  • 07-03-2018

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Seite 1

Gebrauchsinformation: Information für Anwender

Cal-D-or 500 mg/400 I.E. - Kautabletten

Calcium/Vitamin D

Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses

Arzneimittels beginnen, denn sie enthält wichtige Informationen.

Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen.

Wenn Sie weitere Fragen haben, wenden Sie sich an Ihren Arzt oder Apotheker.

Dieses Arzneimittel wurde Ihnen persönlich verschrieben. Geben Sie es nicht an Dritte weiter.

Es kann anderen Menschen schaden, auch wenn diese die gleichen Beschwerden haben wie Sie.

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt

auch für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind. Siehe Abschnitt

Was in dieser Packungsbeilage steht

Was sind Cal-D-or - Kautabletten und wofür werden sie angewendet?

Was sollten Sie vor der Einnahme von Cal-D-or - Kautabletten beachten?

Wie sind Cal-D-or - Kautabletten einzunehmen?

Welche Nebenwirkungen sind möglich?

Wie sind Cal-D-or - Kautabletten aufzubewahren?

Inhalt der Packung und weitere Informationen

1.

Was sind Cal-D-or - Kautabletten und wofür werden sie angewendet?

Cal-D-or - Kautabletten sind ein Calciumpräparat in Kombination mit Vitamin D

, wobei beide

Substanzen eine wichtige Rolle in der Knochenbildung einnehmen. Cal-D-or – Kautabletten werden

zur Vorbeugung und Behandlung von Vitamin D- und Calcium-Mangelzuständen bei älteren

Menschen und zur Unterstützung einer spezifischen Osteoporose-Therapie verwendet.

2.

Was sollten Sie vor der Einnahme von Cal-D-or - Kautabletten beachten?

Cal-D-or - Kautabletten dürfen nicht eingenommen werden,

wenn Sie allergisch gegen Calcium, Vitamin D oder einen der in Abschnitt 6. genannten sonstigen

Bestandteile dieses Arzneimittels sind.

wenn Sie schwere Nierenprobleme haben

bei erhöhtem Calciumspiegel im Blut oder im Harn.

bei Nierensteinen.

bei erhöhtem Vitamin D-Spiegel im Blut.

Warnhinweise und Vorsichtsmaßnahmen

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker bevor Sie Cal-D-or Kautabletten einnehmen,

wenn Sie Cal-D-or – Kautabletten über einen längeren Zeitraum einnehmen. Im Besonderen, wenn

Sie auch Diuretika (verwendet zur Behandlung von Bluthochdruck oder Ödemen) oder

herzwirksame Glykoside (verwendet zur Behandlung von Herzerkrankungen) einnehmen.

wenn Sie Anzeichen für eine eingeschränkte Nierenfunktion oder eine ausgeprägte Neigung zu

Nierensteinbildung haben.

wenn Sie an Sarkoidose leiden (einer Erkrankung des Immunsystems, die den Vitamin D-Spiegel

ansteigen lassen kann).

wenn Sie an Osteoporose mit gleichzeitiger Bewegungseinschränkung leiden.

wenn Sie andere Vitamin D-Präparate einnehmen. Zusätzliche Einnahmen von Calcium und

Vitamin D dürfen nur unter strenger medizinischer Aufsicht erfolgen.

Kinder

Seite 2

Cal-D-or – Kautabletten sind nicht für die Anwendung bei Kindern geeignet.

Einnahme von Cal-D-or - Kautabletten zusammen mit anderen Arzneimitteln

Informieren Sie Ihren Arzt oder Apotheker, wenn Sie andere Arzneimittel einnehmen/anwenden,

kürzlich andere Arzneimittel eingenommen/angewendet haben oder beabsichtigen andere Arzneimittel

einzunehmen/anzuwenden.

Bei Einnahme von Tetracyclin-haltigen Arzneimitteln kann die Aufnahme von Tetracyclin ins Blut

durch die gleichzeitige Einnahme von Calciumcarbonat beeinträchtigt werden. Aus diesem Grund

müssen Tetracyclin-haltige Arzneimittel mindestens zwei Stunden vor bzw. vier bis sechs Stunden

nach der Einnahme von Cal-D-or - Kautabletten eingenommen werden.

Bei gleichzeitiger Behandlung mit Bisphosphonat-Präparaten müssen diese mindestens eine Stunde

vor Cal-D-or eingenommen werden.

Calcium kann die Wirkung von Levothyroxin herabsetzen. Aus diesem Grund sollte Levothyroxin

mindestens vier Stunden vor oder vier Stunden nach Cal-D-or – Kautabletten eingenommen werden.

Bei gleichzeitiger Einnahme von Calcium kann die Wirksamkeit von Chinolon-Antibiotika

herabgesetzt werden. Daher sollten Chinolon-Antibiotika zwei Stunden vor oder sechs Stunden nach

Cal-D-or – Kautabletten eingenommen werden.

Calciumsalze können die Aufnahme von Eisen, Zink und Strontiumranelat herabsetzen. Daher sollten

Präparate, die Eisen, Zink oder Strontiumranelat enthalten, mindestens zwei Stunden vor oder nach

Cal-D-or – Kautabletten eingenommen werden.

Andere Arzneimittel die möglicherweise mit Cal-D-or – Kautabletten wechselwirken:

Thiazid-Diuretika und Herzglykoside.

Orlistat (zur Behandlung von Adipositas) kann die Resorption von fettlöslichen Vitaminen (z.B.

Vitamin D

) beeinträchtigen.

Wenn Sie eines der oben genannten Arzneimittel einnehmen, wird Ihnen Ihr Arzt weitere

Anweisungen geben.

Einnahme von Cal-D-or - Kautabletten zusammen mit Nahrungsmitteln und Getränken

Cal-D-or – Kautabletten können mit oder ohne einer Mahlzeit/einem Getränk eingenommen werden.

Schwangerschaft, Stillzeit und Fortpflanzungsfähigkeit

Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger zu sein oder beabsichtigen,

schwanger zu werden, fragen Sie vor der Einnahme dieses Arzneimittels Ihren Arzt oder Apotheker

um Rat.

Wenn während der Schwangerschaft ein Calcium- und Vitamin D-Mangel auftritt, können Cal-D-or -

Kautabletten eingenommen werden.

Während der Schwangerschaft darf die tägliche Einnahme 2500 mg Calcium und 4000 I.E. Vitamin D

pro Tag nicht überschreiten, da Überdosierungen das ungeborene Kind schädigen können.

Cal-D-or - Kautabletten können während der Stillzeit eingenommen werden. Calcium und Vitamin D

gehen in die Muttermilch über. Dies ist zu berücksichtigen, wenn Sie Ihrem Kind zusätzlich Vitamin

D verabreichen.

Verkehrstüchtigkeit und Fähigkeit zum Bedienen von Maschinen

Cal-D-or hat keinen bekannten Einfluss auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen

von Maschinen.

Cal-D-or Kautabletten enthalten Isomalt und Saccharose

Seite 3

Cal-D-or – Kautabletten enthalten Isomalt (E953) und Saccharose. Wenn Ihnen Ihr Arzt gesagt hat,

dass Sie einige Zucker nicht vertragen, fragen Sie Ihren Arzt, bevor Sie dieses Arzneimittel

einnehmen.

3.

Wie sind Cal-D-or - Kautabletten einzunehmen?

Nehmen Sie dieses Arzneimittel immer genau nach Absprache mit Ihrem Arzt ein. Fragen Sie bei

Ihrem Arzt oder Apotheker nach, wenn Sie sich nicht sicher sind.

Dosierung:

Die empfohlene Dosis ist zweimal täglich eine Tablette. Die Tablette kann zerkaut oder gelutscht

werden.

Anwendung bei Kindern

Cal-D-or Kautabletten sind nicht für die Einnahme durch Kinder vorgesehen.

Wenn Sie eine größere Menge von Cal-D-or - Kautabletten eingenommen haben, als Sie sollten

Wenden Sie sich unverzüglich an Ihren Arzt oder Apotheker, falls Sie eine größere Menge von Cal-D-

or – Kautabletten eingenommen haben als Sie sollten.

Wenn Sie die Einnahme von Cal-D-or - Kautabletten vergessen haben

Nehmen Sie nicht die doppelte Menge ein, wenn Sie die vorherige Einnahme vergessen haben.

4.

Welche Nebenwirkungen sind möglich?

Wie alle Arzneimittel kann auch dieses Arzneimittel Nebenwirkungen haben, die aber nicht bei jedem

auftreten müssen.

Überempfindlichkeitsreaktionen sind mit unbekannter Häufigkeit aufgetreten (die Häufigkeit kann auf

Grundlage der verfügbaren Daten nicht abgeschätzt werden). Wenn eines der folgenden Symptome bei

Ihnen auftritt, müssen Sie umgehend einen Arzt kontaktieren: Anschwellen von Gesicht, Zunge,

Lippen (Angioödem) oder Anschwellen des Rachens (Kehlkopfödem).

Gelegentliche Nebenwirkungen (kann bis zu 1 von 100 Behandelten betreffen)

Bei hohen Dosen kann es zu erhöhtem Calciumspiegel im Blut (Hypercalcämie) oder erhöhter

Calciumausscheidung im Harn (Hypercalcurie) kommen.

Seltene Nebenwirkungen (kann bis zu 1 von 1000 Behandelten betreffen)

Verstopfung, Verdauungsstörungen, Blähungen, Übelkeit, Magenschmerzen, Durchfall

Sehr seltene Nebenwirkungen (kann bis zu 1 von 10 000 Behandelten betreffen)

Juckreiz, Hautausschlag und Nesselsucht, Milch-Alkali-Syndrom (auch als Burnett-Syndrom

bezeichnet; tritt normalerweise nur nach übermäßiger Calciumeinnahme auf) mit folgenden

Symptomen: häufiger Harndrang, Kopfschmerzen, Appetitverlust, Übelkeit oder Erbrechen,

ungewöhnliche Müdigkeit oder Schwäche, zusammen mit erhöhten Calciumblutwerten und

Nierenfunktionsstörungen.

Wenn Sie an einer Nierenfunktionsstörung leiden, besteht ein Risiko für erhöhte Phosphatwerte im

Blut, Nierensteinbildung und erhöhtes Calcium in den Nieren.

Meldung von Nebenwirkungen

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt auch

für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind. Sie können

Nebenwirkungen auch direkt über das nationale Meldesystem anzeigen:

Seite 4

Bundesamt für Sicherheit im Gesundheitswesen

Traisengasse 5

1200 Wien

Österreich

Fax: + 43 (0) 50 555 36207

Website: www.basg.gv.at

Indem Sie Nebenwirkungen melden, können Sie dazu beitragen, dass mehr Informationen über die

Sicherheit dieses Arzneimittels zur Verfügung gestellt werden.

5.

Wie sind Cal-D-or - Kautabletten aufzubewahren?

Bewahren Sie dieses Arzneimittel für Kinder unzugänglich auf.

Sie dürfen dieses Arzneimittel nach dem auf dem Umkarton und dem Etikett nach „Verwendbar bis:“

angegebenen Verfalldatum nicht mehr verwenden. Das Verfalldatum bezieht sich auf den letzten Tag

des angegebenen Monats.

Plastikflasche: Nicht über 30 ºC lagern. In der Originalverpackung aufbewahren, um den Inhalt vor

Licht zu schützen. Die Flasche fest verschlossen halten, um den Inhalt vor Feuchtigkeit zu schützen.

Blister: Nicht über 25 °C lagern. In der Originalpackung aufbewahren, um den Inhalt vor Feuchtigkeit

zu schützen. Den Blister im Umkarton aufbewahren, um den Inhalt vor Licht zu schützen.

Entsorgen Sie Arzneimittel nicht im Abwasser oder Haushaltsabfall. Fragen Sie Ihren Apotheker, wie

das Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr verwenden. Sie tragen damit zum Schutz der

Umwelt bei.

6.

Inhalt der Packung und weitere Informationen

Was Cal-D-or - Kautabletten enthalten:

Die Wirkstoffe einer Tablette sind:

1250 mg Calciumcarbonat (entsprechend 500 mg Calcium)

400 I.E. (10 Mikrogramm) Colecalciferol (Vitamin D

Die sonstigen Bestandteile sind:

Xylitol (E967), Povidon, Isomalt (E953), Zitronenaroma, Magnesiumstearat, Sucralose (E955), Mono-

und Diglyceride von Fettsäuren, Tocopherol, Saccharose, modifizierte Maisstärke, mittelkettige

Triglyceride, Natriumascorbat und hochdisperses Siliciumdioxid

Wie Cal-D-or - Kautabletten aussehen und Inhalt der Packung

Cal-D-or – Kautabletten sind runde, weiße Kautabletten. Diese können kleine Flecken aufweisen.

Packungsgrößen:

Tablettenbehältnis mit HDPE Schraubverschluss: 20, 30, 50, 60, 90, 100, 120, 168 und 180 Tabletten

Blister: 20, 30, 50, 50 x 1 (Einzeldosen), 60, 90, 100, 120, 168 und 180 Tabletten

Es werden möglicherweise nicht alle Packungsgrößen in Verkehr gebracht.

Pharmazeutischer Unternehmer und Hersteller:

Zulassungsinhaber

Takeda Austria GmbH

St. Peter Straße 25

Seite 5

4020 Linz, Österreich

Hersteller

Cal-D-or – Kautabletten in Plastikflaschen:

Takeda AS

Drammensveien 852

NO-1383 Asker, Norwegen

oder

Takeda Pharma AS

55B Jaama Street,

63308 Polva, Estland

Cal-D-or – Kautabletten in Blisterpackungen:

Tjoapack Netherlands B.V.

Nieuwe Donk 9

4879 AC Etten-Leur, Niederlande

oder

Takeda Pharma AS

55B Jaama Street

63308 Polva, Estland

Dieses Arzneimittel ist in den Mitgliedsstaaten des Europäischen Wirtschaftsraumes (EWR)

unter den folgenden Bezeichnungen zugelassen:

Belgien: Steovit D

citroen 500 mg/400 I.E.

Dänemark: Calcichew-D

Forte

Finnland: Calcichew D

Forte sitruuna 500 mg/10 mikrog

– purutabletti

Griechenland: Calcioral D

Luxemburg: Steovit D

citron 500 mg/400 I.E.

Niederlande: Calci-Chew D

500 mg/400 I.E., kauwtabletten

Norwegen: Calcigran Forte

Polen: Orocal D

Lemon

Schweden: Calcichew-D

Citron

Slowakei: Calcichew-D3

Spanien: Mastical D sabor limón 500mg/400 UI comprimidos masticables

Tschechien: CALCICHEW D3 400 IU žvýkací tablety

Ungarn: Calcichew-D3 500 mg/400 NE rágótabletta

Z.Nr.: 1-22817

Diese Gebrauchsinformation wurde zuletzt überarbeitet im März 2017.

11-12-2018

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications

FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings.

FDA - U.S. Food and Drug Administration

11-12-2018

Inspired Organics Issues Voluntary Recall of Organic Sunflower Butter Due to Potential Health Risk

Inspired Organics Issues Voluntary Recall of Organic Sunflower Butter Due to Potential Health Risk

Inspired Organics, LLC has issued a voluntary recall of Organic Sunflower Butter due to potential contamination of Listeria monocytogenes. Listeria monocytogenes is an organism, which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria infection can cause miscarriages...

FDA - U.S. Food and Drug Administration

10-12-2018

FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs

FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs

FDA clears a mobile medical application (app) to help increase retention (the amount of time a patient participates) in an outpatient treatment program for individuals with opioid use disorder

FDA - U.S. Food and Drug Administration

10-12-2018

The J.M. Smucker Company Issues Voluntary Recall of Specific Lots of 9Lives® Protein Plus® Wet, Canned Cat Food Due to Low Levels of Thiamine (Vitamin B1)

The J.M. Smucker Company Issues Voluntary Recall of Specific Lots of 9Lives® Protein Plus® Wet, Canned Cat Food Due to Low Levels of Thiamine (Vitamin B1)

The J.M. Smucker Company today announced a voluntary recall of specific lots of 9Lives® Protein Plus® wet, canned cat food due to possible low levels of thiamine (Vitamin B1). No illnesses related to this issue have been reported to date and the product is being recalled out of an abundance of caution.

FDA - U.S. Food and Drug Administration

7-12-2018

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Laboratoire RivaInc. and Laboratoires Trianon Inc. are voluntarily recalling five over-the-counter strawberry-flavoured acetaminophen oral drops for infants. The products are labeled as Biomedic, Option, Personnelle, Selection, or Laboratoires Trianon Inc. The products are packaged in 24 mL bottles and are used for pain and fever relief. They are being recalled because the child-resistant safety cap may be defective. This recall is in addition to previous recalls of children’s acetaminophen syrups for th...

Health Canada

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

6-12-2018

Kroger Louisville Division Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

Kroger Louisville Division Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

Following a recall by Sunshine Mills, Inc., the Kroger Louisville division announced it has removed from sale Abound Chicken & Brown Rice Recipe dog food produced by the supplier. The dog food was sold in one Kroger store located at 2440 Bardstown Road in Louisville, KY. Only Abound Chicken & Brown Rice Recipe dog food with the listed UPC numbers and Best by Dates are affected by this recall. The recall was initiated because the product had the potential to contain an elevated level of Vitamin D, which ...

FDA - U.S. Food and Drug Administration

6-12-2018

King Soopers and City Market Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

King Soopers and City Market Recalls Abound Chicken and Brown Rice Dog Food Because of Elevated Vitamin D Levels

Following a recall by Sunshine Mills, Inc., King Soopers announced it has removed from sale Abound Chicken & Brown Rice Recipe dog food produced by Sunshine Mills, Inc. sold in King Soopers and City Market stores, located in Colorado, Utah, New Mexico and Wyoming. Only Abound Chicken & Brown Rice Recipe dog food with the listed UPC numbers and Best by Dates are affected by this recall. The recall was initiated because the product had the potential to contain an elevated level of Vitamin D, which may caus...

FDA - U.S. Food and Drug Administration

6-12-2018

Danone North America Issues Allergy Alert and Recall for Light & Fit Greek Crunch S’mores Flavor

Danone North America Issues Allergy Alert and Recall for Light & Fit Greek Crunch S’mores Flavor

Danone North America is voluntarily recalling 3,521 cases of Light & Fit® Greek Crunch Nonfat Yogurt & Toppings S’Mores Flavor sold in the United States with an expiration date of December 30, 2018 and UPC of 36632 03825. It was discovered that some of the toppers sold on the product contain peanuts and are improperly labeled. People who have an allergy to peanuts run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

6-12-2018

Expanded Recall: Skip Hop expands recall on Tuo Convertible High Chairs

Expanded Recall: Skip Hop expands recall on Tuo Convertible High Chairs

The front legs on the highchair can detach from the seat, posing a fall and injury hazard to children.

Health Canada

5-12-2018

Chukar Cherries Expands Recall of Ultra Dark Chocolate Product Due to Undeclared Milk

Chukar Cherries Expands Recall of Ultra Dark Chocolate Product Due to Undeclared Milk

Chukar Cherries of Prosser, WA expands a recall on Ultra Dark Chocolate product because it may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

5-12-2018

Hiland Dairy Announces Voluntary Recall of Hiland Dairy Half-Gallon Whole Chocolate Milk

Hiland Dairy Announces Voluntary Recall of Hiland Dairy Half-Gallon Whole Chocolate Milk

Hiland Dairy is announcing a voluntary recall of half-gallon premium whole milk chocolate that is produced at the Kansas City, Missouri facility, over concerns the products may contain eggnog that could affect those individuals that have sensitivity to egg allergens. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

29-11-2018

Gemini Food Corporation Conducts Voluntary Recall of Imperial Taste Fried Red Onions and Fried Garlic Due to Undeclared Wheat

Gemini Food Corporation Conducts Voluntary Recall of Imperial Taste Fried Red Onions and Fried Garlic Due to Undeclared Wheat

Gemini Food Corporation has voluntarily recalled all Imperial Taste Fried Red Onions & Fried Garlic canisters as a precautionary measure because it’s missing an allergen statement and the ingredient panel does not include wheat.

FDA - U.S. Food and Drug Administration

29-11-2018

ELM Pet Foods Recall of Dry Dog Food Due to Elevated Levels of Vitamin D

ELM Pet Foods Recall of Dry Dog Food Due to Elevated Levels of Vitamin D

ELM Pet Foods, Inc is issuing a voluntary recall of Elm Chicken and Chickpea Recipe dog food because the products could contain elevated levels of Vitamin D.

FDA - U.S. Food and Drug Administration

28-11-2018

ANF Pet Inc. Issues Voluntary Precautionary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

ANF Pet Inc. Issues Voluntary Precautionary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

ANF, Inc. is issuing a voluntary recall of select products of ANF Pet Lamb and Rice Dog Food (reference below) due to potentially elevated levels of Vitamin D.

FDA - U.S. Food and Drug Administration

27-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on how modern predicates can promote innovation and advance safety and effectiveness of medical devices that use 510(k) pathway

Statement from FDA Commissioner Scott Gottlieb, M.D., on how modern predicates can promote innovation and advance safety and effectiveness of medical devices that use 510(k) pathway

FDA Commissioner statement on modernizing the 510(k) pathway by creating policies that rely on newer predicates with modern characteristics related to their safety and performance

FDA - U.S. Food and Drug Administration

27-11-2018

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carc...

FDA - U.S. Food and Drug Administration

27-11-2018

Sunshine Mills, Inc. Issues Voluntary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

Sunshine Mills, Inc. Issues Voluntary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

Sunshine Mills, Inc. is issuing a voluntary recall of select products of Evolve Puppy, Sportsman’s Pride Large Breed Puppy and Triumph Chicken and Rice Dog Food (reference below) due to potentially elevated levels of Vitamin D.

FDA - U.S. Food and Drug Administration

26-11-2018

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of Six Lots of Thermacare® Heatwraps Due to Leaking Wraps With The Potential For Skin Injuries

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of Six Lots of Thermacare® Heatwraps Due to Leaking Wraps With The Potential For Skin Injuries

Pfizer Consumer Healthcare, a division of Pfizer Inc., is voluntarily recalling six lots of ThermaCare® HeatWrap product to the consumer level. Pfizer Consumer Healthcare initiated this recall because product from these lots has a potential to leak ingredients that are contained in the heat cell wrap.

FDA - U.S. Food and Drug Administration

26-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of

FDA provides updates on two elements in medical device safety action plan: modernizing 510(k) program and new process for establishing special controls.

FDA - U.S. Food and Drug Administration

23-11-2018

FDA Classifies Field Action Related to Fc 500™ And Epics® As Class 1 Recall Beckman Coulter Life Sciences Committed to Helping Customers Take Prompt, Appropriate Actions

FDA Classifies Field Action Related to Fc 500™ And Epics® As Class 1 Recall Beckman Coulter Life Sciences Committed to Helping Customers Take Prompt, Appropriate Actions

Beckman Coulter Life Sciences today announced the previously communicated global voluntary recall launched in January 2018 related to the FC 500™ Series Flow Cytometers (FC 500), COULTER® EPICS® XL™ and COULTER® EPICS® XL-MCL™ Flow Cytometer with System II Software (together referred to as the EPICS) has been classified as Class 1 by the U.S. Food and Drug Administration (FDA).

FDA - U.S. Food and Drug Administration

23-11-2018

Teva Canada Product Recall (2018-11-23)

Teva Canada Product Recall (2018-11-23)

Health Canada

23-11-2018

Dilart and Dilart HCT (valsartan)

Dilart and Dilart HCT (valsartan)

Recall - potential contamination

Therapeutic Goods Administration - Australia

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

20-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on FDA’s updates to Medical Device Safety Action Plan to enhance post-market safety

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on FDA’s updates to Medical Device Safety Action Plan to enhance post-market safety

FDA provides updates on medical device safety action plan describing recent actions we’ve taken to enhance device safety including implementation of NEST and registries on women’s health.

FDA - U.S. Food and Drug Administration

17-11-2018

The Quaker Oats Company Issues Voluntary Recall of a Small Quantity of Cap’n Crunch’s Peanut Butter Crunch Cereal Distributed to Five Target Stores Due to Possible Health Risk

The Quaker Oats Company Issues Voluntary Recall of a Small Quantity of Cap’n Crunch’s Peanut Butter Crunch Cereal Distributed to Five Target Stores Due to Possible Health Risk

The Quaker Oats Company, a subsidiary of PepsiCo, Inc., today announced a voluntary recall of a small quantity of Cap’n Crunch’s Peanut Butter Crunch cereal due to the potential presence of Salmonella. While the potentially affected product only reached five specific Target stores and is limited to 21 boxes of one variety with two Best Before Dates, Quaker is initiating the voluntary recall to protect public health.

FDA - U.S. Food and Drug Administration

17-11-2018

Recall of Green Cedar Dairy Ackawi Cheese Bearing a Sell by Date of March 26, 2019 or Later

Recall of Green Cedar Dairy Ackawi Cheese Bearing a Sell by Date of March 26, 2019 or Later

Routine samples of the Green Cedar Ackawi cheese collected and tested by the U.S. Food and Drug Administration and the Michigan Department of Agriculture and Rural Development tested positive for the presence of Listeria monocytogenes.

FDA - U.S. Food and Drug Administration

14-11-2018

Nor Cal Food Solutions, LLC ISSUES ALLERGY ALERT ON UNDECLARED Tree Nut – Walnut in The Purveyors Kitchen - Pumpkin Pesto Tapenade

Nor Cal Food Solutions, LLC ISSUES ALLERGY ALERT ON UNDECLARED Tree Nut – Walnut in The Purveyors Kitchen - Pumpkin Pesto Tapenade

Nor Cal Food Solutions, LLC of Auburn, CA is announcing a recall of 567 cases of Pumpkin Pesto Tapenade, manufactured by Purveyors Kitchen, because it contains an undeclared tree nut (walnut). People who have an allergy or severe sensitivity to tree nuts (walnuts) run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

13-11-2018

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

On September 26, 2018 Oscor notified customers of a recall for certain lots (Recall No. 1035166- 09/07/2018-01-R) of TB Unshrouded Bipolar Pacing Leads. As part of the recall correction activities, Oscor is retrieving any remaining inventory out in the field. The recall scope is being expanded to include expired inventory for devices distributed between December 21, 2011 to May 17, 2018. The recall expansion is to ensure proper disposition of expired units. The FDA has been notified and is aware Oscor In...

FDA - U.S. Food and Drug Administration

13-11-2018

Alebrije Dist Wholesale Recalls Quesillo Queseria “La Milagrosa” and “Alebrije Cheese” Because of Possible Health Risk

Alebrije Dist Wholesale Recalls Quesillo Queseria “La Milagrosa” and “Alebrije Cheese” Because of Possible Health Risk

ALEBRIJE DIST WHOLESALE is collaborating with health officials due to a positive finding of Salmonella in a sample of Quesillo “Queseria La Milagrosa”. ALEBRIJE DIST WHOLESALE is voluntarily recalling the amount of 100 kilos of Quesillo “Queseria La Milagrosa”. While “Alebrije Cheese” has not been found positive for Salmonella, ALEBRIJE DIST WHOLESALE has decided to voluntarily recall the specific 498 “Alebrije Cheese” pieces that were imported during the same period out of an abundance of caution.

FDA - U.S. Food and Drug Administration

10-11-2018

Recall of Bittersweet & Feve Chocolate Bars Due to High Levels of Milk Allergens

Recall of Bittersweet & Feve Chocolate Bars Due to High Levels of Milk Allergens

Today, Recchiuti Confections (San Francisco, CA) discovered two batches of their Bittersweet Chocolate Bar and two batches of their Feve Chocolate Bar contain high levels of milk protein after FDA sampling. No illnesses have been reported to date. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products. The chocolate bars can be enjoyed if you do not have milk allergies or sensitivities. Recchiuti Confections is...

FDA - U.S. Food and Drug Administration

9-11-2018

FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse

FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse

U.S. Marshals Service has conducted a mass seizure of FDA-regulated products that were being held in an Arkansas grocery warehouse under insanitary conditions

FDA - U.S. Food and Drug Administration

9-11-2018

Natural Life Pet Products Expands Recall of Dry Food Due to Elevated Levels of Vitamin D

Natural Life Pet Products Expands Recall of Dry Food Due to Elevated Levels of Vitamin D

We regret to inform you that Natural Life® Chicken & Potato dry dog food has been confirmed to contain elevated levels of Vitamin D.

FDA - U.S. Food and Drug Administration

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

9-11-2018

Medical Devices Safety Update, Volume 6, Number 6, November 2018

Medical Devices Safety Update, Volume 6, Number 6, November 2018

Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests

Therapeutic Goods Administration - Australia

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.

FDA - U.S. Food and Drug Administration

8-11-2018

Wegmans Food Markets, Inc. Issues Allergy Alert on Undeclared Milk in Wegmans Pumpkin Loaf, 11 oz., and Wegmans Placek Coffee Cake, 11 oz. and 22 oz.

Wegmans Food Markets, Inc. Issues Allergy Alert on Undeclared Milk in Wegmans Pumpkin Loaf, 11 oz., and Wegmans Placek Coffee Cake, 11 oz. and 22 oz.

Wegmans has initiated a voluntary recall of the following products because they may contain milk not declared on the label. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

7-11-2018

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be sterile, are manufactured without necessary production controls and conditions to assure sterility.

FDA - U.S. Food and Drug Administration

6-11-2018

Duncan Hines Classic White, Classic Butter Golden, Signature Confetti and Classic Yellow Cake Mixes Recalled Due to Potential Presence of Salmonella

Duncan Hines Classic White, Classic Butter Golden, Signature Confetti and Classic Yellow Cake Mixes Recalled Due to Potential Presence of Salmonella

Conagra Brands is collaborating with health officials in connection with a positive finding of Salmonella in a retail sample of Duncan Hines Classic White cake mix that may be linked to a Salmonella outbreak that is currently being investigated by CDC and FDA. While it has not been definitively concluded that this product is linked to the outbreak and the investigation is still ongoing, Conagra has decided to voluntarily recall the specific Duncan Hines variety identified (Classic White) and three other ...

FDA - U.S. Food and Drug Administration

11-12-2018

Regulation of Software as a Medical Device

Regulation of Software as a Medical Device

Updated information on the regulation of Software as a Medical Device

Therapeutic Goods Administration - Australia

10-12-2018

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more:  https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

. @US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDA pic.twitter.com/HiJbgPnsPt

FDA - U.S. Food and Drug Administration

2-12-2018

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies to advance these efforts pic.twitter.com/2co2Hz4jUt

FDA - U.S. Food and Drug Administration

30-11-2018

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of  blood glucose monitors to empower patients with diabetes with reliable  tools to manage their health. Read more:  https://go.usa.gov/xPMyA   #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall:  https://go.usa.gov/xPMEn  #MedicalDevicepic.twitter.com/YU9Iq

.@US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall: https://go.usa.gov/xPMEn  #MedicalDevicepic.twitter.com/YU9Iq

. @US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall: https://go.usa.gov/xPMEn  #MedicalDevice pic.twitter.com/YU9Iq3Yw0b

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA issues class I recall, the most serious type pf recall: Zimmer  Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack  of Adequate Validation and Controls to Ensure Product Cleanliness. Read  more about the recall:  https://go.us

.@US_FDA issues class I recall, the most serious type pf recall: Zimmer Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack of Adequate Validation and Controls to Ensure Product Cleanliness. Read more about the recall: https://go.us

. @US_FDA issues class I recall, the most serious type pf recall: Zimmer Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack of Adequate Validation and Controls to Ensure Product Cleanliness. Read more about the recall: https://go.usa.gov/xPMEK  #MedicalDevice pic.twitter.com/M55ddC98wW

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

. @US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

FDA - U.S. Food and Drug Administration

28-11-2018

Use of market authorisation evidence from comparable overseas regulators / assessment bodies for medical devices (including IVDs)

Use of market authorisation evidence from comparable overseas regulators / assessment bodies for medical devices (including IVDs)

Clarification of ISO 13485 certificates for IVD medical devices

Therapeutic Goods Administration - Australia

27-11-2018

Reclassification of surgical mesh medical devices

Reclassification of surgical mesh medical devices

New guidance to assist sponsors with the reclassification of surgical mesh devices

Therapeutic Goods Administration - Australia

26-11-2018

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do:  https://go.usa.gov/xPHtk   #FDA #MedicalDevice

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do: https://go.usa.gov/xPHtk  #FDA #MedicalDevice

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do: https://go.usa.gov/xPHtk  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

26-11-2018

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Actio

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Actio

We believe in merits of 510(k) process, but also believe it must be modernized to reflect advances in technology, safety, capabilities of newer devices. It’s time to fundamentally modernize an approach first adopted in 1976 c/w Medical Device Safety Action we issued in April 2018

FDA - U.S. Food and Drug Administration

26-11-2018

Today #FDA announced the most significant modernization of the 510(k) medical device review process in a generation. https://www.wsj.com/articles/fda-is-revamping-clearance-procedures-for-medical-devices-1543234015 …

Today #FDA announced the most significant modernization of the 510(k) medical device review process in a generation. https://www.wsj.com/articles/fda-is-revamping-clearance-procedures-for-medical-devices-1543234015 …

Today #FDA announced the most significant modernization of the 510(k) medical device review process in a generation. https://www.wsj.com/articles/fda-is-revamping-clearance-procedures-for-medical-devices-1543234015 …

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

23-11-2018

.@US_FDA issues Class I Medical Device Recall, the most serious type of   recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to  Connector Separation Causing Potential for Loss of Pacing. Find out  more:  https://go.usa.gov/xPHxF  #FDA #MedicalDe

.@US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDe

. @US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDevice pic.twitter.com/negJ6HU4x2

FDA - U.S. Food and Drug Administration

23-11-2018

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more:  https://go.usa.gov/xPHxf   #FDA #MedicalDevice

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more: https://go.usa.gov/xPHxf  #FDA #MedicalDevice

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more: https://go.usa.gov/xPHxf  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

21-11-2018

EU/3/18/2096 (Hansa Medical AB)

EU/3/18/2096 (Hansa Medical AB)

EU/3/18/2096 (Active substance: Imlifidase) - Orphan designation - Commission Decision (2018)7806 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/093/18

Europe -DG Health and Food Safety

20-11-2018

.@US_FDA issues update to safety communication warning against the use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures. Read more:  https://go.usa.gov/xPAzk  #MedicalDevicepic.twitter.com/pv0k2yaNfj

.@US_FDA issues update to safety communication warning against the use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures. Read more: https://go.usa.gov/xPAzk  #MedicalDevicepic.twitter.com/pv0k2yaNfj

. @US_FDA issues update to safety communication warning against the use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures. Read more: https://go.usa.gov/xPAzk  #MedicalDevice pic.twitter.com/pv0k2yaNfj

FDA - U.S. Food and Drug Administration

20-11-2018

.@US_FDA has updated the webpage on Urogynecologic Surgical Mesh Implants. Read more:  https://go.usa.gov/xPAzD  #MedicalDevice

.@US_FDA has updated the webpage on Urogynecologic Surgical Mesh Implants. Read more: https://go.usa.gov/xPAzD  #MedicalDevice

. @US_FDA has updated the webpage on Urogynecologic Surgical Mesh Implants. Read more: https://go.usa.gov/xPAzD  #MedicalDevice

FDA - U.S. Food and Drug Administration

20-11-2018

.@US_FDA issues Class I Medical Device Recall, the most serious type of recall: Beckman Coulter Life Sciences Beckman Coulter Life Sciences recalls the FC500 Series Flow Cytometers and EPICS XL Series Flow Cytometers. Find out more:  https://go.usa.gov/xP

.@US_FDA issues Class I Medical Device Recall, the most serious type of recall: Beckman Coulter Life Sciences Beckman Coulter Life Sciences recalls the FC500 Series Flow Cytometers and EPICS XL Series Flow Cytometers. Find out more: https://go.usa.gov/xP

. @US_FDA issues Class I Medical Device Recall, the most serious type of recall: Beckman Coulter Life Sciences Beckman Coulter Life Sciences recalls the FC500 Series Flow Cytometers and EPICS XL Series Flow Cytometers. Find out more: https://go.usa.gov/xPAtn  #MedicalDevice #FDA pic.twitter.com/6e064UQ2wg

FDA - U.S. Food and Drug Administration

14-11-2018

The @US_FDA issues a safety communication cautioning doctors & patients of the risks associated w/ using medications that are not approved for use w/ implanted pumps that are delivered into the spinal fluid to treat or   manage pain:  https://go.usa.gov/x

The @US_FDA issues a safety communication cautioning doctors & patients of the risks associated w/ using medications that are not approved for use w/ implanted pumps that are delivered into the spinal fluid to treat or manage pain: https://go.usa.gov/x

The @US_FDA issues a safety communication cautioning doctors & patients of the risks associated w/ using medications that are not approved for use w/ implanted pumps that are delivered into the spinal fluid to treat or manage pain: https://go.usa.gov/xPfuw  #FDA #MedicalDevice pic.twitter.com/kgDSx2PQzn

FDA - U.S. Food and Drug Administration

7-11-2018

ACMD meeting statement, Meeting 43, 11 October 2018

ACMD meeting statement, Meeting 43, 11 October 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia